**Bioorthogonal Self-Immolative Linker Based on Grob Fragmentation**

Xhenti Ferhati, Marina Salas-Cubero, Pablo Garrido, Josune García-Sanmartín, Ana Guerreiro, Alberto Avenoza, Jesús H. Busto, Jesús M. Peregrina, Alfredo Martínez, Ester Jiménez-Moreno, Gonçalo J. L. Bernardes, and Francisco Corzana*

**Cite This:** Org. Lett. 2021, 23, 8580−8584

**ABSTRACT:** A self-immolative bioorthogonal conditionally cleavable linker based on Grob fragmentation is described. It is derived from 1,3-aminocyclohexanols and allows the release of sulfonate-containing compounds in aqueous media. Modulation of the amine pKₐ promotes fragmentation even at slightly acidic pH, a common feature of several tumor environments. The Grob fragmentation can also occur under physiological conditions in living cells, highlighting the potential bioorthogonal applicability of this reaction.

Antibody−drug conjugates (ADCs) are attracting considerable attention due to their high therapeutic potential in cancer treatment. ADCs combine the high selectivity of a monoclonal antibody for a specific target on cancer cells with the toxicity of a drug attached through a linker. Once the ADC has reached its target, the payload can be released. Despite extensive research in ADCs, improvement is still highly desirable, particularly in those related to conditionally activable linker technologies. Two main families of linkers have been developed. “Noncleavable linkers” rely on proteolytic degradation of the antibody upon internalization to release the drug. On the contrary, “cleavable linkers” are designed to release the drug within or in the vicinity of the tumor cell upon a trigger stimulus. In recent years, there have been multiple reports of self-immolative linkers able to self-degrade in a spontaneous and irreversible manner through a cascade-elimination process. This process is, in general, driven by an entropy increase and the formation of thermodynamically stable products. Control of drug release is achieved by a stimulus such as an enzymatic cleavage of the linker that activates the self-immolative process.2−11

The most validated self-immolative linker uses a p-amino benzyl carbamate either coupled to a valine-citrulline (Val-Cit-PAB) or β-glucuronide, which release the cytotoxic payload upon cathepsin B or β-glucuronidase cleavage, respectively.12 These linkers have been successfully translated into the clinic; for example, Adcetris has been approved for the treatment of refractory Hodgkin’s lymphoma.13 In the last years, a range of self-immolative linkers have also been developed such as p-aminobenzyl ethers,14 cinnamyl ethers,15 or cyclization driven linkers16,17 (Figure 1a).

Here, we decided to explore the Grob fragmentation18−20 in the design of self-immolative linkers. Substrates that can undergo Grob fragmentation are 1,3-disubstituted chains bearing a nucleophile with a negative charge or a lone electron pair at position 1, such as a heteroatom (X in Figure 1b), and a leaving group in position 3, such as halogens, sulfonates, or quaternary ammonium salts (represented as a blue sphere in Figure 1b).19 This fragmentation has been widely used in the synthesis of highly demanding macrocyclic structures21 and natural products.22 Typical conditions use organic solvents, high temperatures, and strong bases. Interestingly, isolated reports have used water as a cosolvent in this reaction,23,24 which led us to envision that the Grob fragmentation may be performed under milder conditions found in biological environments.

**Received:** September 27, 2021

**Published:** October 25, 2021
To this purpose, we synthesized compounds 1–3 shown in Figure 2. A secondary amine was chosen as a pushing group because its pKa and thus, the corresponding reaction rate can be modulated by the installation of different substituents. Similarly, sulfonates were selected as leaving groups due to their broad presence in organic molecules with biological applications such as fluorophores. Compound 3 was used as a negative control since the nitrogen lone pair is not available and precludes the Grob fragmentation. This compound is completely stable in a mixture of CD3CN/PBS (1:1) buffer with a pH of 7.4 for 48 h at 37 °C, as shown by 1H NMR spectroscopy (Figure S7). The addition of an organic solvent to the buffer is required for the complete solubilization of these compounds.

Compound 1 was also stable in a mixture CH3OH/PBS buffer (pH 7.4) (1:1). However, the fragmentation reaction took place when the pH of the buffer was increased from 7.4 to 8.0. In this case, a mixture of the starting material and the fragmentation product was observed by 1H NMR (Figure S1).

Monitoring the Grob fragmentation of 2c by 1H NMR spectroscopy. The reaction was performed at 5 mM of 2c in CD3CN/PBS pH 7.4 (1:1) at 37 °C (Figure S3). According to the 1H NMR experiments, 69% and 61% of the dansyl sulfonate was released for compound 2c and 2b, respectively, after 48 h. As observed with derivative 1, higher pH values of the buffer led to an increase in the reaction rate and yield (Figure S4).

Interestingly, when dansyl acid is conjugated to our Grob fragmentation scaffolds, the absorbance of this group suffers a red shift, and the absorbance maximum shifts from 312 nm for the free acid to ∼348 nm for derivatives 2c and 3 (Figure 4a). When the latter molecules are excited at 380 nm, they emit fluorescence while free dansyl acid does not. This property was exploited to investigate the potential bioorthogonality of the reaction under physiological conditions. First, we incubated 2c and 3 with cell medium at pH 7.5. As shown in Figure 4b, the fluorescence of compound 3 was retained after 28 h. A similar result was obtained at pH 6.0 (Figure S8), indicating that these acidic conditions are not strong enough to cleave the Boc and prompt the corresponding fragmentation. The reaction under strongly acidic conditions could favor the cleavage of the carbamate. At the same time, however, these conditions may reduce (as shown above) or hinder the rate of fragmentation since the amino group is likely to remain in the fully protonated form. On the contrary, the fluorescence decreases significantly for compound 2c at pH 6.0 and 7.5 after 4 h (Figures 4b and S8), indicating that fragmentation of this molecule takes place successfully under biological conditions, in agreement with our previous NMR study.
Finally, we investigated the use of the fluorogenic derivative 2c in living cells by confocal microscopy. To this end, we used compounds 2c and 3, which were nontoxic to the cell line SH-SY SY after 24 h of treatment with a wide range of concentrations (Figure S9). As mentioned above, both derivatives produce a fluorescent signal in the violet region (excitation 405 nm, emission 420–470 nm) and can be captured by the confocal microscope (Figure 4c). However, when the Grob reaction takes place, two fragments are obtained that do not generate signal in this spectrum. Briefly, cells were treated with compounds 2c and 3 (20 μM) for 24 h. At this time, cells were imaged by confocal microscopy, and surprisingly, the loss of blue fluorescence in compound 2c was observed as the result of the successful Grob fragmentation. On the other hand, the fluorescence intensity of compound 3 did not change over time (Figure S10). Finally, it is important to note that the substrates of Grob fragmentation undergo side reactions such as substitution, cyclization, or even elimination. However, we have not observed any potential compounds derived from these reactions with our derivatives and under the above experimental conditions.

In summary, we have designed and synthesized a new self-immolative linker based on the Grob fragmentation that allowed the controlled release of sulfonate-containing compounds such as a dansyl group under physiological conditions. We have also tuned conveniently the pKₐ of the pushing group (amino group) using different substituents, leading to more efficient conversions at physiological pH and in some cases even at acidic pH, which is normally found in tumor environments. In addition, the Grob fragmentation takes place in living cells, demonstrating the potential bioorthogonal applicability of the reaction. On the basis of these promising results, research is currently underway to incorporate this type of linker into antibody–drug conjugates for the targeted delivery of cytotoxic drugs and fluorophores.

■ ASSOCIATED CONTENT

 Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.orglett.1c03299.

General information, synthesis, NMR studies, biology experimental details, confocal microscopy procedures, characterization data (PDF)

■ AUTHOR INFORMATION

Corresponding Authors
Ester Jiménez-Moreno — Departamento de Química, Centro de Investigación en Síntesis Química, Universidad de La Rioja, 26006 Logroño, La Rioja, Spain; orcid.org/0000-0002-5045-433X; Email: ester.jimenez@unirioja.es
Gonçalo J. L. Bernardes — Instituto de Medicina Molecular Joao Lobo Antunes, Faculdade de Medicina de Universidade de Lisboa, 1649-028 Lisboa, Portugal; Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, United Kingdom; orcid.org/0000-0001-6594-8917; Email: gb453@cam.ac.uk
Francisco Corzana — Departamento de Química, Centro de Investigación en Síntesis Química, Universidad de La Rioja, 26006 Logroño, La Rioja, Spain; orcid.org/0000-0001-5597-8127; Email: francisco.corzana@unirioja.es

Authors
Xhenti Ferhati — Departamento de Química, Centro de Investigación en Síntesis Química, Universidad de La Rioja, 26006 Logroño, La Rioja, Spain

https://doi.org/10.1021/acs.orglett.1c03299
Org. Lett. 2021, 23, 8580–8584
Organic Letters

Marina Salas-Cubero — Departamento de Química, Centro de Investigación en Síntesis Química, Universidad de La Rioja, 26006 Logroño, La Rioja, Spain
Pablo Garrido — Angiogenesis Group, Oncology Area, Center for Biomedical Research of La Rioja (CIBIR), 26006 Logroño, Spain; orcid.org/0000-0002-5960-8569
Josune Garcia-Sanmartin — Angiogenesis Group, Oncology Area, Center for Biomedical Research of La Rioja (CIBIR), 26006 Logroño, Spain; orcid.org/0000-0003-4391-5537
Ana Guerreiro — Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina de Universidade de Lisboa, 1649-028 Lisboa, Portugal
Alberto Avenoza — Departamento de Química, Centro de Investigación en Síntesis Química, Universidad de La Rioja, 26006 Logroño, La Rioja, Spain
Jesús H. Busto — Departamento de Química, Centro de Investigación en Síntesis Química, Universidad de La Rioja, 26006 Logroño, La Rioja, Spain; orcid.org/0000-0003-4403-4790
Jesús M. Peregrina — Departamento de Química, Centro de Investigación en Síntesis Química, Universidad de La Rioja, 26006 Logroño, La Rioja, Spain; orcid.org/0000-0003-3778-7065
Alfredo Martinez — Angiogenesis Group, Oncology Area, Center for Biomedical Research of La Rioja (CIBIR), 26006 Logroño, Spain; orcid.org/0000-0003-4882-4044

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.orglett.1c03299

Author Contributions
† X.F. and M.S.-C. contributed equally to this work.

Notes
The authors declare no competing financial interest.

ACKNOWLEDGMENTS
We thank the Agencia Estatal de Investigación of Spain (AEI; Grant No. RTI2018-099592-B-C21). This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Grant Agreement No. 675007. M.S.-C. thanks the Asociación Española Contra el Cáncer AECC (La Rioja) for the predoctoral fellowship. E.J.-M. acknowledges the contract Beatriz Galindo from the Ministry of Universities of Spain.

REFERENCES
(1) Drago, J. Z.; Modi, S.; Chandarlapaty, S. Unlocking the Potential of Antibody–Drug Conjugates for Cancer Therapy. Nat. Rev. Clin. Oncol. 2021, 18, 327–344.
(2) Walther, R.; Rautio, J.; Zelikin, A. N. Prodrugs in Medicinal Chemistry and Enzyme Prodrug Therapies. Adv. Drug Delivery Rev. 2017, 118, 65–77.
(3) Li, X.; Hou, Y.; Meng, X.; Ge, C.; Ma, H.; Li, J.; Fang, J. Selective Activation of a Prodrug by Thioredoxin Reductase Providing a Strategy to Target Cancer Cells. Angew. Chem., Int. Ed. 2018, 57, 6141–6145.
(4) Legigan, T.; Clairhart, J.; Tranoy-Opalsinski, I.; Monvoisin, A.; Renoux, B.; Thomas, M.; Le Pape, A.; Lerondel, S.; Papot, S. The First Generation of β-Galactosidase-Responsive Prodrugs Designed for the Selective Treatment of Solid Tumors in Prodrug Monotherapy. Angew. Chem., Int. Ed. 2012, 51, 11606–11610.
(5) Kim, D. R.; Kim, T. S.; Kim, E.; Min, S. J.; Shin, D.; Ahn, D. R. Synthesis of 3′-O-Fluorescently Mono-Modified Reversible Termini and Their Uses in Sequencing-by-Synthesis. Bioorg. Med. Chem. Lett. 2014, 24, 209–213.
(6) Cazzamalli, S.; Dal Corso, A.; Neri, D. Linker Stability Influences the Anti-Tumor Activity of Acetazolamide-Drug Conjugates for the Therapy of Renal Cell Carcinoma. J. Controlled Release 2017, 246, 39–45.
(7) Haba, K.; Popkov, M.; Shamis, M.; Lerner, R. A.; Barbas, C. F.; III, Shabat, D. Single-Triggered Trimeric Prodrugs. Angew. Chem., Int. Ed. 2005, 44, 716–720.
(8) Ortiz, A.; Shanahan, C. S.; Sisk, D. T.; Perera, S. C.; Rao, P.; McGrath, D. V. Improved Iterative Synthesis of Linearly Disassembling Dendrons. J. Org. Chem. 2010, 75, 6154–6162.
(9) Mosey, R. A.; Floreancig, P. E. Versatile Approach to α-Alkoxyl Carbamate Synthesis and Stimulus-Responsive Alcohol Release. Org. Biomol. Chem. 2012, 10, 7980–7985.
(10) Deng, Z.; Yuan, S.; Xu, R. X.; Liang, H.; Liu, S. Reduction-Triggered Transformation of Crosslinking Modules of Disulphide-Containing Micelles with Chemically Tunable Rates. Angew. Chem., Int. Ed. 2018, 57, 8896–8900.
(11) Yang, Y.; Pan, Z.; Choudhury, M. R.; Yuan, Z.; Anifowose, A.; Yu, B.; Wang, W.; Wang, B. Making smart drugs smarter: The importance of linker chemistry in targeted drug delivery. Med. Res. Rev. 2020, 40, 2682–2713.
(12) Lu, J.; Jiang, F.; Lu, A.; Zhang, G. Linkers Having a Crucial Role in Antibody – Drug Conjugates. Int. J. Mol. Sci. 2016, 17, 561.
(13) Senter, P. D.; Sievers, E. L. The Discovery and Development of Brentuximab Vedotin for Use in Relapsed Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma. Nat. Biotechnol. 2012, 30, 631–637.
(14) Zhang, D.; Le, H.; de la Cruz-Chuh, J.; Bobba, S.; Guo, J.; Staben, L.; Zhang, C.; Ma, Y.; Kozak, K. R.; Lewis Phillips, G. D.; Vollmar, B. S.; Sadowsky, J. D.; Vandlen, R.; Wei, B.; Su, D.; Fan, P.; Dragovich, P. S.; Khojaste, S. C.; Hop, C. E. C. A.; Pillow, T. H. Immolation of P-Aminobenzyl Ether Linker and Payload Potency and Stability Determine the Cell-Killing Activity of Antibody–Drug Conjugates with Phenol-Containing Payloads. Bioconjugate Chem. 2018, 29, 267–274.
(15) Matkonda, S. S.; Fairhall, J. M.; Tyndall, J. D. A.; Hook, S.; Gamble, A. B. Stability, Kinetic, and Mechanistic Investigation of l,8- Self-Immolative Cinnamyl Ether Linkers for Controlled Release of Phenols and Generation of Resonance and Inductively Stabilized Methides. Org. Lett. 2017, 19, 528–531.
(16) Elgersma, R. C.; Coumans, R. G. E.; Huijbrugs, T.; Menge, W. M. P. B.; Joosten, J. A. F.; Spijker, H. J.; De Groot, F. M. H.; Van Der Lee, M. M. C.; Ubink, R.; Van Den Dobbelsteen, D. J.; Egging, D. F.; Dokter, W. H. A.; Verheijden, G. F. M.; Lemmens, J. M.; Timmers, C. M.; Beuker, P. H. Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985. Mol. Pharmacotherm. 2015, 12, 1813–1835.
(17) Hurelle, S.; Alouane, A.; Le Saux, T.; Jullien, L.; Schmidt, F. Syntheses and Kinetic Studies of Cyclisation-Based Self-Immolative Linkers. Org. Biomol. Chem. 2017, 15, 3435–3443.
(18) Grob, C. A.; Schiess, P. W. Heterolytic Fragmentation. A Class of Organic Reactions. Angew. Chem., Int. Ed. Engl. 1967, 6, 1–15.
(19) Grob, C. A. Mechanisms and Stereochimistry of Heterolytic Fragmentation. Angew. Chem., Int. Ed. Engl. 1969, 8, 535–546.
(20) Prantz, K.; Mulzer, J. Synthetic Applications of the Carbonyl Generating Grob Fragmentation. Chem. Rev. 2010, 110, 3741–3766.
(21) Amann, C. M.; Fisher, P. V.; Pugh, M. L.; West, F. G. Medium-Sized Carbocycles and Ethers from 4-Pyrones: A Photocyclization–Fragmentation Approach. J. Org. Chem. 1998, 63, 2806–2807.
(22) Larionov, O. V.; Carey, E. J. An Unconventional Approach to the Enantioselective Synthesis of Caryophyllolids. J. Am. Chem. Soc. 2008, 130, 2954–2955.
(23) Burkhardt, U.; Grob, C. A.; Kiefer, H. R. Die Sterischen Bedingungen Der Fragmentierungsreaktion. II. Teil. Stereoisomere 3-Aminocyclohexyl-p-Tolulosulfonate. Fragmentierungsreaktionen, 15. Mitteilung. Helv. Chim. Acta 1967, 50, 231–244.
(24) Kevill, D. N.; Ryu, Z. H.; D’Souza, M. J. Correlation Analysis of the Rates of Solvolysis of 4-Bromopiperidine: A Reaction Following a Grob Fragmentation Pathway. Eur. J. Chem. 2017, 8, 162−167.
(25) CRC Handbook of Chemistry and Physics, 85th ed.; Lide, D. R., Ed.; CRC Press: Boca Raton, FL, 2005.
(26) Estrella, V.; Chen, T.; Lloyd, M.; Wojtkowiak, J.; Cornnell, H. H.; Ibrahim-Hashim, A.; Bailey, K.; Balagurunathan, Y.; Rothberg, J. M.; Sloane, B. F.; Johnson, J.; Gatenby, R. A.; Gillies, R. J. Acidity Generated by the Tumor Microenvironment Drives Local Invasion. Cancer Res. 2013, 73, 1524−1535.